SELDI-TOF MS whole serum proteomic profiling with IMAC surface does not reliably detect prostate cancer.

Publication Type:

Journal Article


Clinical chemistry, Volume 54, Issue 1, p.53-60 (2008)


2008, ADENOCARCINOMA, Aged, Aged, 80 and over, Bias (Epidemiology), Blood Specimen Collection, Case-Control Studies, Humans, Male, Middle Aged, Prospective Studies, Prostate-Specific Antigen, Prostatic Neoplasms, PROTEOMICS, Public Health Sciences Division, Retrospective Studies, Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization, Tumor Markers, Biological


The analysis of bodily fluids using SELDI-TOF MS has been reported to identify signatures of spectral peaks that can be used to differentiate patients with a specific disease from normal or control patients. This report is the 2nd of 2 companion articles describing a validation study of a SELDI-TOF MS approach with IMAC surface sample processing to identify prostatic adenocarcinoma.